159 related articles for article (PubMed ID: 35952985)
21. Letter regarding - Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
Theodorou DJ; Theodorou SJ; Tzimas V; Korompilias AV
Bone; 2023 Oct; 175():116853. PubMed ID: 37473932
[No Abstract] [Full Text] [Related]
22. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
24. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project.
Porta-Sales J; Garzón-Rodríguez C; Llorens-Torromé S; Brunelli C; Pigni A; Caraceni A
Palliat Med; 2017 Jan; 31(1):5-25. PubMed ID: 27006430
[TBL] [Abstract][Full Text] [Related]
25. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
26. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
Body JJ; von Moos R; Niepel D; Tombal B
BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
[TBL] [Abstract][Full Text] [Related]
27. Denosumab for Fibrous Dysplasia: Promising, but Questions Remain.
Collins MT; de Castro LF; Boyce AM
J Clin Endocrinol Metab; 2020 Nov; 105(11):e4179-80. PubMed ID: 32478399
[No Abstract] [Full Text] [Related]
28. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.
Hendriks LE; Hermans BC; van den Beuken-van Everdingen MH; Hochstenbag MM; Dingemans AM
J Thorac Oncol; 2016 Feb; 11(2):155-73. PubMed ID: 26718881
[TBL] [Abstract][Full Text] [Related]
29. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
Pan KS; Boyce AM
Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
[TBL] [Abstract][Full Text] [Related]
30. Treatment of fibrous dysplasia: focus on denosumab.
Huzum B; Antoniu S; Dragomir R
Expert Opin Biol Ther; 2022 Mar; 22(3):397-405. PubMed ID: 34964677
[TBL] [Abstract][Full Text] [Related]
31. RANKL inhibition halts lesion progression and promotes bone remineralization in mice with fibrous dysplasia.
Liu Z; Yin Y; Wang Z; Xie L; Deng P; Wang D; Ji N; Zhao H; Han X; Chen Q; Chung CH; Bai D; Zhao X
Bone; 2022 Mar; 156():116301. PubMed ID: 34952228
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
Boyce AM; Kelly MH; Brillante BA; Kushner H; Wientroub S; Riminucci M; Bianco P; Robey PG; Collins MT
J Clin Endocrinol Metab; 2014 Nov; 99(11):4133-40. PubMed ID: 25033066
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Denosumab for Fibrous Dysplasia of Bone.
de Castro LF; Michel Z; Pan K; Taylor J; Szymczuk V; Paravastu S; Saboury B; Papadakis GZ; Li X; Milligan K; Boyce B; Paul SM; Collins MT; Boyce AM
N Engl J Med; 2023 Feb; 388(8):766-768. PubMed ID: 36812441
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
35. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
37. Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw.
Metwally T; Burke A; Tsai JY; Collins MT; Boyce AM
J Oral Maxillofac Surg; 2016 Oct; 74(10):1983-99. PubMed ID: 27137436
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone.
Chapurlat RD; Gensburger D; Jimenez-Andrade JM; Ghilardi JR; Kelly M; Mantyh P
Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S3. PubMed ID: 22640953
[TBL] [Abstract][Full Text] [Related]
39. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.
Nadella S; Mupparapu M; Akintoye SO
Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165
[TBL] [Abstract][Full Text] [Related]
40. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia.
Eller-Vainicher C; Rossi DS; Guglielmi G; Beltramini GA; Cairoli E; Russillo A; Mantovani G; Spada A; Chiodini I
Clin Cases Miner Bone Metab; 2016; 13(3):253-256. PubMed ID: 28228794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
